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Abstract
Protein acetylation is a common modification that plays a central role in several cellular processes.
The most widely used methods to study these modifications are either based on the detection of
radioactively acetylated oligopetide products or an enzyme-coupled reaction measuring conversion
of the acetyl donor acetyl CoA to the product CoASH. Due to several disadvantages of these
methods, we designed a new method to study oligopeptide acetylation. Based on reverse phase
HPLC we detect both reaction products in a highly robust and reproducible way. The method
reported here is also fully compatible with subsequent product analysis, e.g. by mass spectroscopy.
The catalytic subunit, hNaa30p, of the human NatC protein N-acetyltransferase complex was used
for N-terminal oligopeptide acetylation. We show that unacetylated and acetylated oligopeptides
can be efficiently separated and quantified by the HPLC-based analysis. The method is highly
reproducible and enables reliable quantification of both substrates and products. It is therefore
well-suited to determine kinetic parameters of acetyltransferases.
Background
Acetylation of proteins is a common protein modification
that occurs either in the N-terminal α amino group (Nα-
acetylation) or the ε amino group of lysine residues (Nε-
acetylation). The corresponding acetylation reactions are
catalysed by Nα-acetyltransferases (NATs) or histone
acetyltransferases/lysine acetyltransferases (HATs/KATs),
respectively [1,2].
The important biological functions of protein acetylation
have promoted extensive functional studies of different
acetyltransferases to determine their kinetic properties,
substrate specificities and catalytic mechanisms. For most
of the enzymatic analyses, two different kinds of acetyl
transfer assays are used. One uses radioactively labelled
acetyl CoA as substrate [3]. The generation of radioac-
tively labelled oligopeptides is monitored by a filter-bind-
ing assay and liquid scintillation counting [3]. This assay
is very sensitive [4], but due to the use of radioactivity, the
assay represents potential environmental and health risks
and it is therefore relatively demanding to perform due to
safety precautions. The other commonly used method is a
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spectrophotometric assay that continuously measures the
amount of CoASH generated by the acetyltransferase reac-
tions [5]. The CoASH is determined by a coupled enzyme
system using either α-ketoglutarate dehydrogenase or
pyruvate dehydrogenase. The CoASH dependent oxida-
tion of α-ketoglutarate or pyruvate is coupled to the
reduction of NAD+ to NADH, which is determined spec-
trophotometrically at 340 nm. This assay is relatively inex-
pensive and can be performed with standard
spectrophotometric equipment. A disadvantage of both
methods is the difficulty to detect whether an oligopep-
tide substrate contains more than one lysine target resi-
due.
Using the production of CoA as the basis for measuring
acetyltransferase activity is linked to another potentially
severe cause of error. In nearly all KAT assays, measuring
the Nε-acetylation of lysines, a substantial amount of
acetyl CoA will spontaneously react with the ε amino
group on lysine side chains, making it necessary to design
proper controls to correct for this effect [4].
In addition, using the CoA-NADH coupled enzyme assay,
it is not possible to use CoA as inhibitor to study acetyl-
transferase catalytic mechanism and, similarly to the filter
assay, when more than one lysine target is present in the
oligopeptide substrate, detailed acetylation site specificity
can not be studied. To determine Km and Vmax values,
the initial reaction rate must be determined under condi-
tions giving linear initial reaction rates over the range of
substrate concentration used, normally the substrate con-
version should not exceed 10 – 15% [4]. Furthermore,
build-up of high concentrations of products may cause
product inhibition. It is therefore of interest to obtain
detailed information both on substrate consumption and
product production. The radioactivity-based filter assay
and the coupled-enzyme assay do not provide informa-
tion on product consumption and detailed control exper-
iments must be added. In the present article, we present a
simple method for studying oligopeptide acetylation,
using reverse phase HPLC detecting acetylated oligopep-
tides, in addition to CoASH. This method uses semi-auto-
mated HPLC-technology providing a fast, sensitive and
highly reproducible assay for protein acetyltransferases.
The instrument records the UV spectrum between 200 and
300 nm, thereby enabling to monitor acetyl CoA and CoA
(260 nm) and the peptide substrate and acetylated oli-
gopeptides (215 nm) simultaneously. In addition, a radi-
oactive flow detector may be connected to detect 14C/3H-
acetyl-oligopeptides to increase sensitivity, if required.
After the peptide separation using reverse phase HPLC,
the relevant absorbance peaks are integrated and the cor-
responding areas are converted to amounts of product
formed. The continuous recording of the UV spectra
allows for each peak to be evaluated for the maximum
absorbance wavelength which can be used to determine
the purity of each absorbance signal.
Since the oligopeptide separation is performed in buffers
containing acetonitrile and TFA, the HPLC method is also
fully compatible with subsequent analytical procedures
such as mass spectrometry to determine the site of modi-
fication.
Methods
Chemicals
Chemicals used in this study that are important for correct
enzymatic determination are acetonitrile – ACN (Merck),
trifluoracetic acid – TFA (Roche), acetyl CoA (Sigma), [1-
14C] acetyl CoA (56 mCi/mmol – GE Healthcare). All rea-
gents were of analytical grade. Custom made oligopep-
tides (Table 1) were purchased from BioGenes, Germany.
Cloning, expression and purification of MBP-hNaa30p
The catalytic subunit of the human NatC complex;
hNaa30p (earlier known as hMak3), a NAT acetyltrans-
ferase, was used to establish the reverse phase HPLC
method. hNAA30 was cloned into the prokaryotic expres-
sion system pETM-MBP (originally obtained from G. Stier
– EMBL, Heidelberg, Germany) and expressed in E. coli.
The cloning, expression and purification were performed
as described [6].
Table 1: Oligopeptides used as substrates in this study
Oligopeptide sequence Abbreviation Protein name¤
[H]MLGTEGG RWGRPVGRRRRPVRVYP [OH]* 1MLGTE-RRR24 hnRNP H; (P31943)
[H]MLALISR RWGRPVGRRRRPVRVYP [OH]* 1MLAL-RRR24 hARL8b; (Q9NVJ2)
[H]MLGTGPA RWGRPVGRRRRPVRVYP [OH]* 1MLGTG-RRR24 mTOR; (P42345)
[H]MLGPEGG RWGRPVGRRRRPVRVYP [OH]* 1MLGP-RRR24 hnRNP F; (P52597)
* Bold indicates amino acids found in corresponding protein while abbreviation indicate the names used in the text. The amino acid residues 8 to 24 
of the oligopeptides are annotated 'RRR' in the text. ¤Name of protein with an N-terminal sequence identical to the seven first amino acids of the 
oligopeptide.BMC Proceedings 2009, 3(Suppl 6):S5 http://www.biomedcentral.com/1753-6561/3/S6/S5
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Separation of non acetylated and acetylated oligopeptides 
using reverse phase HPLC
The acetylation activity was analysed by a reverse phase
HPLC system, consisting of a LC-20AB solvent delivery
module, an SPD-M20A photodiode array detector and a
SIL-20AC autosampler (Shimadzu Prominence), and a
250 mm × 3 mm Nucleosil C18 HD column (Macherey-
Nagel) reverse phase HPLC column. In addition, a radio-
activity flow detector (LB 509 – Berthold) and a peristaltic
pump were connected down stream of the HPLC absorb-
ance detector (Figure 1). All absorbance signals were
quantified by integrating the peak of interest using the
software LCSolution Version 1.21 SP1.
Prior to sample injection, the column was equilibrated for
5 minutes (0.35 ml/min flow rate) with buffer A (5% ace-
tonitrile (ACN) and 0.1% trifluoracetic acid (TFA)). After
sample injection, the column was washed for 8 minutes
with 2% elutionbuffer B (90% ACN, 0.1% TFA). The oli-
gopeptides were then eluted employing a 40 minutes lin-
ear gradient from 2% to 40% buffer B. The column was
then rinsed with 95% buffer B for 5 minutes. Finally, a 2
minutes linear gradient to 2% buffer B was performed.
Determination of steady-state kinetic constants with 
reverse phase HPLC
80 nM of purified MBP-hNaa30p with 200 μM 1MLGTE-
RRR24 oligopeptide and 300 μM acetyl CoA in acetylation
buffer (50 mM Tris-HCl (pH 8.5), 10% Glycerol, 1 mM
EDTA) were incubated for 60 minutes at 37°C. Samples
were collected after 0, 10, 20, 30, and 60 minutes incuba-
tion and analyzed by reverse phase HPLC.
To determine the Km oligopeptides, 80 nM of purified MBP-
hNaa30p was incubated with varying concentrations of
oligopeptides (30 to 350 μM) and 300 μM acetyl CoA in
acetylation buffer for 30 minutes at 37°C. When deter-
mining the Km acetyl CoA, 300 μM of 1MLAL-RRR24 peptide
was used in combination with varying ‘concentrations of
acetyl CoA (4 to 40 µM). The enzyme reactions were
stopped by adding TFA to final concentrations of 1% (v/
v). The amounts of acetylated oligopeptides were deter-
mined based on the absorbance at 215 nm, while the pro-
duction of CoA was determined by using the absorbance
at 260 nm. The steady-state enzyme kinetic parameters
were calculated by nonlinear regression analysis using the
SigmaPlot Technical Graphing Software (SPSS Inc.) The
normality tests for all Km determinations were passed
with value > 0.8.
To verify the elution time for the acetylated oligopeptides,
we conducted a time dependent acetylation assay by incu-
bating purified MBP-hNaa30p (80 nM) with the oli-
gopeptide  1MLGTE-RRR24 (200  μM) and [1-14C] acetyl
CoA (final concentration 300 μM with specific activity
11.2 mCi/mmol). Samples were collected after 0, 10, 20,
30, and 60 minutes, placed on ice and adjusted to 1%
TFA.
Results
The HPLC system
To establish the chromatographic procedure, first, the elu-
tion times for unmodified oligopeptides were determined
by injecting 3 nmol of pure oligopeptides diluted in the
acetylation buffer on the HPLC system. Then we tested
whether unacetylated and acetylated oligopeptides could
be efficiently separated. We incubated an oligopeptide
that is expected be a good hNaa30p substrate [7];
1MLGTE-RRR24 (200 μM) and 300 μM acetyl CoA with 80
nM of purified MBP-hNaa30p in the acetylation buffer.
The sample was incubated at 37°C with aliquots collected
after 0, 10, 20, 30, and 60 minutes (see Methods). From
the elution profile at Abs 215 nm, we observed, as
expected, a large amount of unmodified oligopeptide
(Figure 2A, peak annotated 'a') and an additional peak
with delayed elution time which increased with enzyme
reaction time (Figure 2A and 2B, peak annotated 'b'). The
changes in absorbance profiles recorded at 260 nm,
detecting CoA and acetyl CoA in the same run, showed the
same tendencies as the Abs 215 nm signals (Figure 3A and
3B). We observed a large excess of acetyl CoA (Figure 3A,
peak annotated 'b') and an additional peak that increases
during the course of the reaction (Figure 3A and 3B, peak
annotated 'a'). The elution times of acetyl CoA and CoA
were determined by injecting 3 nmol of CoA or acetyl CoA
and recording the resulting absorbance profiles. This anal-
ysis showed that CoA and acetyl CoA eluted after 6 min-
utes and 9 minutes and 30 seconds, respectively, peaks 'a'
and 'b' in Figure 3A.
Analysing the sensitivity of the method
The sensitivity of the HPLC based analysis was studied by
injecting different amounts of oligopeptide and recording
the resulting Abs 215 nm signal. The sensitivity for acetyl
Schematic presentation of the HPLC system included the  equipment needed to detect the radioactivity Figure 1
Schematic presentation of the HPLC system 
included the equipment needed to detect the radio-
activity.BMC Proceedings 2009, 3(Suppl 6):S5 http://www.biomedcentral.com/1753-6561/3/S6/S5
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CoA was determined by injecting different amounts of
acetyl CoA and recording the resulting Abs 260 nm signal.
A linear correlation between the absorbance signals and
the amount of substrates added was observed (Figure 4A
and 4B). We noted that 0.5 nmol was the lower limit for
reliable quantification of oligopeptides at 215 nm, which
corresponded to 5 μM in a reaction volume of 100 μl.
To enhance the detection sensitivity and to verify that the
novel delayed absorption peak represented oligopeptides
with one added acetyl group, we connected a radioactive
flow detector after the absorbance detector (Figure 1).
This allowed us to use radioactively labelled acetyl CoA as
acetyl donor. To prevent background accumulation of
radioactivity in the solid scintillator detector system, 1 M
NaOH was mixed to the column effluent in a 1:10 mixing
ratio by connecting a peristaltic pump in-line between the
absorbance detector and the radioactivity flow detector
(Figure 1). High concentration of NaOH was used so that
the dilution of the samples, thus dilution of the radioac-
tive signals was as low as possible. Using [1-14C] acetyl
CoA as acetyl donor in the reaction, we observed a similar
increase in radioactively labelled acetylated oligopeptides
(Figure 5) as observed for the Abs 215 nm absorption sig-
nal (Figure 2B, peak 'b'). This verifies that the peptide with
delayed elution time is labelled with radioactive acetyl
groups and that the quantity of the signal increased with
enzyme reaction time.
Quantification of CoA has the potential of generating 
false kinetic data
Our results indicated that the HPLC system is a solid
method to study peptide acetylation. Using the non-radi-
oactive HPLC method to detect the amount of acetylated
oligopeptides, we determined hNaa30p enzyme kinetic
constants for some in vitro oligopeptide substrates. Differ-
ent concentrations of 1MLGTG-RRR24 peptides (30–350
μM) were used with fixed concentration of acetyl CoA
(300 μM) and 80 nM of purified MBP-hNaa30p. When
using the absorption signal at 215 nm, representing
acetylated oligopeptides, we calculated the Km oligopeptide to
be 283 μM with Vmax of 3.3 pmol * min-1 * pmol
hNaa30p-1 (Table 2). In the same run, the production of
CoA was recorded at 260 nm and used to calculate the cor-
Reverse phase HPLC absorbance profile of the separation of  CoA and acetyl CoA Figure 3
Reverse phase HPLC absorbance profile of the sepa-
ration of CoA and acetyl CoA. A; The oligopeptide 
1MLGTE-RRR24 (200 μM) was incubated with acetyl CoA 
(300 μM) and purified MBP-hNaa30p (80 nM) in acetylation 
buffer for 60 minutes at 37°C. Samples were collected at 
indicated time points and analysed with reverse phase HPLC. 
The resulting absorbance profile at 260 nm indicates good 
separation of CoA ('a') and acetyl CoA ('b'). B; An expanded 
version of the absorbance profile for the formation of CoA. 
A time dependent increase in the absorption signal is 
observed.
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Reverse phase HPLC absorbance profile at 215 nm for the  separation of acetylated and non-acetylated peptides Figure 2
Reverse phase HPLC absorbance profile at 215 nm 
for the separation of acetylated and non-acetylated 
peptides. A; The oligopeptide 1MLGTE-RRR24 (200 μM) 
was incubated with acetyl CoA (300 μM) and purified MBP-
hNaa30p (80 nM) in acetylation buffer for 60 minutes at 
37°C. Samples were collected at indicated time points and 
analysed with reverse phase HPLC. The resulting absorbance 
profile at 215 nm indicate good separation of unacetylated 
('a') and acetylated oligopeptides ('b'). B; An expanded ver-
sion of the absorbance profile for the formation of acetylated 
oligopeptide. A clear time dependent increase in the absorp-
tion signal is observed.
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responding kinetic constants. Here we observed that the
Michaelis Menten plot based on CoA production gener-
ated a dose dependent curve from which a significantly
lower Vmax was obtained (Figure 6) compared to when
Vmax was calculated based on the production of
acetylated oligopeptides (Figure 7). Km oligopeptide based on
CoA production was determined to be 3.1 μM with a
Vmax of 8.7 pmol * min-1 * pmol hNaa30p-1 (Table 2). It
is important to note that approximately eight pmoles
CoASH (Figure 6) were produced per pmole acetylated
oligopeptide (Figure 7). Since theoretically one mole
CoASH should be generated per mole acetylated oli-
gopeptide, a discrepancy in CoASH production relative to
acetylated oligopeptide was apparent. Km for acetyl CoA
were with non linear regression determined to be approx-
imately 14 μM with a Vmax of 2.1 pmol * min-1 * pmol
hNaa30p-1 (Figure 8). V/K for selected substrates was cal-
culated (Figure 9) and the S.D., indicated by error bars,
were determined based on three independent experi-
ments. The data demonstrate that substrate selectivity of
the enzyme can be readily detected by the HPLC method.
Discussion and conclusion
The radioactivity-based filter assay [3] and the CoA-
NADH coupled enzyme assay [5] are the most commonly
applied methods to study acetyltransferase kinetics and
mechanisms. Both these methods suffer from significant
drawbacks such as biohazard and non-enzymatic
deacetylation of acetyl CoA. To eliminate these problems
and to allow us to analyse the acetylated oligopeptide
products by mass spectrometry, we developed a method
for studying peptide acetylation based on reverse phase
Table 2: Comparison of Km oligopeptide and Vmax based on the detection of CoA(260 nm) and the detection of acetylated oligopeptides(215 
nm).
CoA Ac-1MLGTG-RRR24
Km (μM) Vmax (pmol product * min-1 * pmol hNaa30p-1)K m  ( μM) Vmax (pmol product * min-1 * pmol hNaa30p-1)
3.1 8.7 283.2 3.3
Standard curves of increasing amount of the substrate  1MLGP-RRR24 and acetyl CoA analysed by reverse phase  HPLC Figure 4
Standard curves of increasing amount of the sub-
strate 1MLGP-RRR24 and acetyl CoA analysed by 
reverse phase HPLC. A; Five different amounts of the oli-
gopeptide 1MLGP-RRR24, diluted in acetylation buffer, were 
analysed by reverse phase HPLC. The resulting absorption 
signals at 215 nm were quantified. Each amount were ana-
lysed three times and error bars indicate S.D. B; Five differ-
ent amounts of acetyl CoA, diluted in acetylation buffer, 
were analysed by reverse phase HPLC. The resulting absorp-
tion signals at 260 nm were quantified. Each amount were 
analysed three times and error bars indicate S.D.
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The radioactive signal from oligopeptides being modified with  radioactive acetyl CoA Figure 5
The radioactive signal from oligopeptides being mod-
ified with radioactive acetyl CoA. The oligopeptide 
1MLGTE-RRR24 (200 μM) was incubated with [1-14C] acetyl 
CoA (final 300 μM with specific activity 11.2 mCi/mmol) and 
purified MBP-hNaa30p (80 nM) in acetylation buffer for 60 
minutes at 37°C. Samples were collected at indicated time 
points and analysed with reverse phase HPLC that had been 
connected to a radioactivity flow detector after the absorb-
ance detector. A clear time dependent increase in the radio-
activity signal is observed, verifying that the eluted 
oligopeptides are labelled with radioactive acetyl groups.
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HPLC. After acetylation, non-acetylated and acetylated
oligopeptides are separated and quantified by integrating
the respective elution peaks.
Since the first residues of the substrates seem to be most
important for enzyme specificity [1], we designed pep-
tides that deviated only within the 7 first N-terminal posi-
tions. The next 17 amino acids that are indicated by 'RRR'
are identical in all peptides and resemble the sequence of
Adrenocorticotropic hormone (ACTH) (Amino acid no. 8
to 24), but all Lys residues were replaced with Arg to min-
imize aberrant N-ε acetylation. The separation of peptides
were carried out with 0.1% TFA in the HPLC buffers, mak-
ing the peptide residues highly protonated. The positively
charged Arg residues facilitate peptide solubility and sep-
aration by reverse phase HPLC. The N-terminal acetyla-
tion substitutes a positive charge by a hydrophobic group,
causing the acetylated oligopeptides to be separated from
the non acetylated form due to stronger interaction with
the Nucleosil C18 HD matrix, resulting in increased elu-
tion time. Several acetylation assays with other Nα-acetyl-
transferases acetylating oligopeptides containing more
hydrophobic residues, showed that the acetylated form of
these oligopeptides also could be efficiently separated
with the reverse phase Nucleosile C18HD column. This
indicates that commercially available oligopeptide sub-
strates, composed of the endogenous amino acids, can be
used as substrates with this detection method.
The unacetylated and acetylated oligopeptide 1MLGTE-
RRR24 was separated by more than 3 minutes. Even when
using high amounts of oligopeptides, >30 nmols, leading
to a widening of the peaks, an efficient separation of
unacetylated and acetylated oligopeptides was achieved. If
necessary, the separation of oligopeptides can be further
enhanced by optimising the elution profile.
The sensitivity of the detection method was determined
by injecting different amount of oligopeptides and acetyl
CoA and quantifying the resulting absorption profiles.
This showed a clear linear trend for both substrates, span-
ning from 0.5 to 5 nmol of acetyl CoA and from 1 to 10
nmol of oligopeptide. The coefficient of determination
Determination of Km and Vmax for the 1MLGTG-RRR24 oli- gopeptide, based on the generation of acetylated 1MLGTG- RRR24 oligopeptide Figure 7
Determination of Km and Vmax for the 1MLGTG-
RRR24 oligopeptide, based on the generation of 
acetylated 1MLGTG-RRR24 oligopeptide. Purified MBP-
hNaa30p (80 nM) was incubated with 300 μM acetyl CoA 
and varying concentrations of 1MLGTG-RRR24 (30 – 350 μM) 
in acetylation buffer for 30 minutes at 37°C. A; Non linear 
regression analysis of the dose dependent curve generated 
based on the analysis of the acetylated oligopeptide absorp-
tion signal at 215 nm. The coefficient of determination (R2) is 
given above the plot. B; Hanes-Woolf plot of the dose 
dependent acetylation signal.
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Determination of Km and Vmax for the 1MLGTG-RRR24 oli- gopeptide, based on the generation of CoA Figure 6
Determination of Km and Vmax for the 1MLGTG-
RRR24 oligopeptide, based on the generation of CoA. 
Purified MBP-hNaa30p (80 nM) was incubated with 300 μM 
acetyl CoA and varying concentrations of 1MLGTG-RRR24 
(30 – 350 μM) in acetylation buffer for 30 minutes at 37°C. 
A; Non linear regression analysis of the dose dependent 
curve generated based on the analysis of the CoA absorption 
signal at 260 nm. The coefficient of determination (R2) is 
given above the plot. B; Hanes-Woolf plot of the dose 
dependent acetylation signal.
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(R2) was above 0.97 for both substrates. Our experience
with this acetylation assay is that even at very high
amounts of oligopeptides, up to 30 nmol, the increase in
absorbance at 215 nm is linear with coefficient of deter-
mination above 0.97 (data not shown).
The reproducibility of the method was analysed by calcu-
lating the standard deviation (S.D.) from three independ-
ent experiments. This was done for the sensitivity
determination and the calculation of the kinetic con-
stants. The result demonstrated that the reverse phase
HPLC method is highly reproducible when analysing
acetylation based on the detection of acetylated oligopep-
tides with the Abs 215 nm signal.
In conclusion, we have established a robust and highly
reproducible method for studying oligopeptide acetyla-
tion. With new semi-automated reverse phase HPLC tech-
nology, we show that both substrates, acetyl CoA and
unacetylated oligopeptides, and enzyme products, CoA
and acetylated oligopeptides can be detected and quanti-
fied in the same experiment. This allows for increased
control over substrate conversion and product generation
forming a solid basis for data intepretation. Importantly,
the assay is easy to perform and automation reduces sam-
ple handling.
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